Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin-Reference-Cited by-同舟云学术

Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin

Published:2015-06 Issue:3 Volume:108 Page:e67-e70
ISSN:0168-8227
Container-title:Diabetes Research and Clinical Practice
language:en
Short-container-title:Diabetes Research and Clinical Practice

Author:

Wang Man-man,Lin Shuo,Chen Yan-ming,Shu Jiong,Lu Hong-yun,Zhang Yong-jun,Xie Ru-ying,Zeng Long-yi,Mu Pan-wei

Funder

Guangdong Pharmaceutical Association

Publisher

Elsevier BV

Subject

Endocrinology,General Medicine,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference20 articles.

1. ‘Glycaemic variability’: a new therapeutic challenge in diabetes and the critical care setting;Ceriello;Diabet Med,2010

2. Glycemic variability: the third component of the dysglycemia in diabetes. Is it important? How to measure it?;Monnier;J Diabetes Sci Technol,2008

3. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison;Wang;Clin Ther,2011

4. Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin;Kusunoki;Endocr J,2013

5. Global guideline for type 2 diabetes;International Diabetes Federation Guideline Development Group;Diabetes Res Clin Pract,2014

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of DPP-4 Inhibitors and Metformin Combinations in Type 2 Diabetes: A Systematic Literature Review and Network Meta-Analysis;Diabetes, Metabolic Syndrome and Obesity;2024-06

2. DPP-4 Inhibitor Improved the Cognitive Function in Diabetic Rats;Journal of Healthcare Engineering;2022-11-18

3. Acarbose-metformin is more effective in glycemic variability control than repaglinide-metformin in T2DM patients inadequately controlled with metformin: a retrospective cohort study;PeerJ;2020-10-02

4. Acarbose With Comparable Glucose-Lowering but Superior Weight-Loss Efficacy to Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials;Frontiers in Endocrinology;2020-06-05

5. Head-to-Head Comparison of the Hypoglycemic Efficacy and Safety Between Dipeptidyl Peptidase-4 Inhibitors and α-Glucosidase Inhibitors in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials;Frontiers in Pharmacology;2019-07-10